Keyphrases
Adjusted Hazard Ratio
11%
After Surgery
12%
Androgen Deprivation Therapy
34%
Arsenic
13%
Autoimmune Disease
9%
Benign Prostatic Hyperplasia
19%
Bladder Cancer
18%
Bladder Cuff Excision
16%
Bladder Neck Contracture
13%
Breast Cancer Cells
9%
Cancer-specific Survival
14%
Castration-resistant Prostate Cancer
13%
Clinical Experience
12%
Clinical Outcomes
10%
Clinically Significant Prostate Cancer
12%
Comorbidity
10%
Complication Rate
18%
Confidence Interval
43%
Disease-free Survival
13%
Elderly Patients
12%
Escherichia Coli
10%
Estrogen
10%
Extracorporeal Shock Wave Lithotripsy
11%
Hand-assisted Retroperitoneoscopic Donor Nephrectomy
10%
Hazard Ratio
16%
High Risk
14%
Insufflation
9%
Kidney
19%
Laparoscopic Adrenalectomy
9%
Laparoscopic Partial Nephrectomy
45%
Laparoscopic Radical Prostatectomy
9%
Laparoscopic Surgery
18%
Laparoscopy
10%
Latanoprost
11%
Magnetic Resonance Imaging
16%
Meta-analysis
9%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
10%
Monoamine Oxidase A (MAO-A)
14%
Multiparametric MRI (mpMRI)
10%
Multivariate Analysis
10%
National Cohort Study
48%
National Health Insurance Research Database (NHIRD)
10%
Nephroureterectomy
31%
Neuroendocrine Differentiation
9%
Neuroendocrine Prostate Cancer
12%
Newly Diagnosed
13%
No Significant Difference
11%
Non-muscle Invasive Bladder Cancer (NMIBC)
12%
Odds Ratio
12%
Oncological Outcomes
18%
Operative Time
20%
Overall Survival
13%
Overexpression
9%
Partial Nephrectomy
10%
Patients with Prostate Cancer
14%
Percutaneous Nephrolithotomy
14%
Perioperative Complications
9%
Pharmacokinetics
11%
Population-based Study
27%
Porcine Model
12%
Postpartum Depression
11%
Prostate
23%
Prostate Cancer
76%
Prostate Cancer Cells
21%
Prostate Cancer Patients
18%
Prostate Cancer Screening
14%
Prostate Health Index
13%
Prostate-specific Antigen
10%
Radical Cystectomy
12%
Radical Prostatectomy
16%
Recurrence-free Survival
9%
Renal Cell Carcinoma
19%
Renal Tissue
9%
Retroperitoneoscopic
10%
Risk Factors
17%
Scabies
26%
Shock Wave Lithotripsy
10%
Single-center Experience
17%
Single-center Study
9%
Stone-free Rate
17%
Surgical Outcomes
10%
Systematic Meta-analysis
12%
Taipei
39%
Taiwan
100%
Taiwanese
14%
Thulium Laser
15%
Traditional Chinese Medicine
9%
Transitional Cell Carcinoma
20%
Transrectal Biopsy
10%
Transurethral Resection of Prostate
21%
Tumor
26%
Tumor Size
10%
Upper Tract Urothelial Carcinoma
42%
Ureter
19%
Ureteral Stone
10%
Urinary Tract Infection
10%
Urolithiasis
11%
Urothelial Carcinoma
16%
Varicocele
11%
Younger Schoolchildren
9%
Medicine and Dentistry
Adrenal Incidentaloma
6%
Adrenal Tumor
9%
Adrenalectomy
15%
Adverse Event
9%
Amine Oxidase (Flavin Containing) Isoenzyme A
7%
Androgen Deprivation Therapy
13%
Autoimmune Disease
6%
Biopsy Technique
22%
Bladder
45%
Bladder Cancer
15%
Bladder Neck
6%
Bladder Neck Stenosis
13%
Bleeding
18%
Body Mass Index
12%
Cancer Diagnosis
8%
Cancer Specific Survival
9%
Cancer Staging
6%
Castration Resistant Prostate Cancer
12%
Cell Signaling Pathway
12%
Clear Cell Renal Cell Carcinoma
21%
Cohort Analysis
34%
Comorbidity
9%
Computer Assisted Tomography
12%
Cystectomy
18%
Diabetes Mellitus
6%
Disease Free Survival
11%
Diseases
22%
Elderly Patient
9%
Emergency Department
7%
Extracorporeal Shock Wave Lithotripsy
9%
Gleason Score
6%
Hazard Ratio
22%
Hernioplasty
8%
Hormone Therapy
8%
Incision
17%
Infection
11%
Intraocular Pressure
7%
Kidney Blood Flow
6%
Kidney Function
8%
Kidney Stone
25%
Laparoscopic Surgery
36%
Ligation
15%
Lithotripsy
21%
Magnetic Resonance Imaging
15%
Malignant Neoplasm
16%
Messenger RNA
7%
Meta-Analysis
6%
Metastatic Carcinoma
8%
Minimally Invasive Procedure
6%
Mitochondrion
9%
Mitogen Activated Protein Kinase 3
7%
Multivariate Analysis
9%
Neoplasm
55%
Nephrectomy
16%
Nephroureterectomy
51%
Non Muscle Invasive Bladder Cancer
8%
Odds Ratio
19%
Operation Duration
19%
Overall Survival
17%
Partial Nephrectomy
25%
Pelvis
12%
Percutaneous Nephrolithotomy
14%
Peroperative Complication
12%
Pheochromocytoma
8%
Pneumoperitoneum
6%
Pneumoretroperitoneum
6%
Postoperative Complication
7%
Prevalence
8%
Programmed Cell Death
9%
Proportional Hazards Model
11%
Prostate Biopsy
14%
Prostate Cancer
77%
Prostate Hypertrophy
12%
Prostate Specific Antigen
20%
Prostatectomy
22%
Radiation Therapy
9%
Recurrence Free Survival
6%
Recurrent Disease
16%
Retreatment
6%
Retrospective Study
14%
Scabies
26%
Shock Wave
12%
Staghorn Stone
6%
Surgeon
7%
Surgery
17%
Survival Rate
8%
Systematic Review
6%
Testes
10%
Thulium
15%
Transitional Cell Carcinoma
68%
Transrectal Ultrasonography
18%
Transurethral Resection
23%
Upper Urinary Tract
26%
Ureter
14%
Ureter Stone
9%
Urinary Retention
9%
Urinary System
17%
Urinary Tract
11%
Urinary Tract Infection
8%
Urothelial Cancer
8%